A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer

Targeted Oncology · Published 2025-10-14 · DOI 10.1007/s11523-025-01175-z

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s11523-025-01175-z

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2025

Related articles